FACULTY PROFILES

Yong Qin

Associate Professor
Pharmacy

Office Building: Campbell Building
Office Room: 508
Phone:
Email: yqin@utep.edu

Bio

As a tenure-track Assistant Professor at UTEP, I have a strong background in cancer immunology and pharmaceutical sciences. My research focuses on drug discovery and biomarker identification for drug-resistant cancers.

Awards and Honors

The 2025 High Impact and Innovative Teaching Award, The University of Texas at El Paso - The University of Texas at El Paso (11/05/2025)
The School of Pharmacy P3 Teacher of the Year - The University of Texas at El Paso (05/01/2025)
The R&I Rising Researcher Award – UTEP Health (Health Sciences, Nursing, & Pharmacy) & Social Sciences, The University of Texas at El Paso - The University of Texas at El Paso (03/01/2025)
UTEP On-Campus Student Internship Awards (2024-2025) - The University of Texas at El Paso (08/06/2024)
P3 Teacher of the Year, The School of Pharmacy at the University of Texas at El Paso, - The School of Pharmacy at the University of Texas at El Paso (07/01/2023)
The American Association of Colleges of Pharmacy (AACP) Teacher of the Year - The American Association of Colleges of Pharmacy (07/01/2023)
The Lizanell and Colbert Coldwell Foundation Research Grant - The Lizanell and Colbert Coldwell Foundation (05/01/2023)
NATIONAL EYE INSTITUTE (FED) SURE R16 Grant - NIH - NATIONAL EYE INSTITUTE (09/01/2022)
UTEP On-Campus Student Internship Awards (2022 -2023) - The University of Texas at El Paso (08/01/2022)
DOD Idea Award in Cancer Research (US Army Medical Research & Material CMD) - DOD (US Army Medical Research & Material CMD) (12/01/2020)
Top 35 Abstracts, 5th Annual IMMUNO-ONCOLOGY Young Investigators’ Forum - IMMUNO-ONCOLOGY Young Investigators’ Forum (01/01/2019-12/31/2019)
AACR‐Millennium Scholar-in-Training Award - American Association for Cancer Research (01/01/2013-12/31/2013)
Trainee Excellence Award - The University of Texas MD Anderson Cancer Center (01/01/2012-12/31/2012)
AACR-OSI Pharmaceutical Scholar-in-Training Award - American Association for Cancer Research (01/01/2007-12/31/2007)

Education

Clinical Research, The Society of Clinical Research Associates (SOCRA) (2017)
Postdoctoral Fellow, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (2014)
Ph D in Pharmaceutical Science, University of Arizona (2008)
MS in Pharmacognosy & Microbial-Biochemical Medicine, Peking Union Medical College (2002)
B.Pharm. in Microbial-Biochemical Medicine (Micropharmaceutics), Shenyang Pharmaceutical Univer (1997)

Publications

Advances in Immunotherapy for Metastatic Uveal Melanoma: Current Progress and Future Direction Journal of Clinical Medicine (2025), Yong Qin.
Development of a Human Colorectal Carcinoma Cell-Based Platform for Studying Inducible Nitric Oxide Synthase Expression and Nitric Oxide Signaling Dynamics Frontiers in Molecular Biosciences (2025), Yong Qin.
S-nitrosylation of p53 under nitrosative stress in melanoma cells International Journal of Molecular Sciences (2025), Mariana Grigoruta, Yong Qin.
Targeting IRS-1/2 in uveal melanoma inhibits in vitro cell growth, survival and migration, and in vivo tumor growth Cancers (Basel) 14(24) (2022), Chandrani Chattopadhyay, Rajat Bhattacharya, Jason Roszik, Fatima Khan, Gabrielle A. Wells, Hugo Villanueva, Yong Qin, Rishav Bhattacharya, Sapna Patel, Elizabeth . Grimm.
Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. European Journal of Medicinal Chemistry 230 (2022), Huiqiang Wei , Wenfeng Gou, Jun Gao, Hongxin Ning, Yang Song, Deguan Li, Yong Qin, Wenbin Hou, Yiliang Li.
Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. Cancers 13 13 (2021), A Ballhausen, E Urias, S K. Gruschkus, M Williams, M S. Glover, Yong Qin, D S. Gombos, S P. Patel.
iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in oncology 11 (2021), Z Ding, D Ogata, J Roszik, Yong Qin, S H. Kim, M T. Tetzlaff, A J. Lazar, M A. Davies, S Ekmekcioglu, E A. Grimm.

Presentations

Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2025), Volume Juarez, Chihuahua , Yong Qin.
Adenosine-driven immune profile in breast cancer (2025), Volume Chicago, Yong Qin.
Immune profiling of CRC identifies a potential signature associated with immunosuppression (2025), Volume Chicago, Yong Qin.
Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2025), Volume Istanbul, Turkey, Yong Qin.
Molecular and Immune Profiling of Hispanic Gastrointestinal Cancer Disparities (2024), Volume Bethesda, MD, USA, Yong Qin.
Development of a novel pan-chemokine receptor inhibitor as therapeutic for breast cancer (2023), Volume Orlando, Florida, Yong Qin.
S-nitrosylation of p53 in melanoma alters p53-DNA binding and downstream gene expression (2023), Volume Orlando, Florida, Jordan Winfield, Yong Qin.
Immune Profile and Immunosuppresive Mechanism of Uveal Melanoma (2022), Volume El Paso, Texas, Yong Qin.
Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2021), Volume Seoul, Korea, Yong Qin.

Grants

U54 Project 1: Targeting the immunosuppressive adenosine pathway to release blockade of T-cell γc cytokine signaling networks and enhance antitumor immunity in hepatocellular carcinoma (04/01/2025 - 03/30/2030) - NIH
SOCS1 AS A CRUCIAL REGULATOR FOR RESISTANT UVEAL MELANOMA RESPONSE TO IMMUNOTHERAPY (09/01/2022 - 08/31/2026) - NIH - NATIONAL EYE INSTITUTE (FED)
ON-CAMPUS INTERNSHIP PROGRAM Award (08/06/2024 - 08/05/2025) - The University of Texas at El Paso
Eno1, a key modulator and drug target for the tumor microenvironment of cervical cancer (03/01/2024 - 02/28/2025) - Lizanell and colbert coldwell foundation
Novel PHD2/HDACs hybrid inhibitors as therapeutics for advanced cervical cancer (05/01/2023 - 01/31/2024) - The Lizanell and Colbert Coldwell Foundation
Development of novel therapeutics to overcome abemaciclib resistance in various cancers (01/16/2023 - 08/31/2023) - The University Research Institute (URI) Award, University of Texas at El Paso, The
Molecular and immune profiling of Hispanic gastrointestinal cancer disparities (03/01/2022 - 02/28/2023) - Border Biomedical Research Center (BBRC) Pilot Projects (NIH), the University of Texas at El Paso

Current/Future Courses

Term	Course	Section	Syllabus
Fall 2026	ESE 6399 - Dissertation	15120
Fall 2026	ESE 6296 - Doctoral Research	18434
Fall 2026	ESE 6396 - Doctoral Research	10067
Fall 2026	ESE 6396 - Doctoral Research	10068
Fall 2026	ESE 6396 - Doctoral Research	12281
Fall 2026	PHAR 6471 - ISBP IIA2	12662
Fall 2026	PHAR 6203 - Pathophysiology & Immunology	15437	Syllabus

Past Courses

Select Term:

Term	Course	Section	Syllabus
Spring 2026	ESE 6398 - Dissertation	21438
Spring 2026	ESE 6396 - Doctoral Research	20235
Spring 2026	ESE 6396 - Doctoral Research	23192
Spring 2026	PHAR 6477 - ISBP IIIB2	23778
Fall 2025	ESE 6396 - Doctoral Research	10072
Fall 2025	ESE 6396 - Doctoral Research	10073
Fall 2025	PHAR 6471 - ISBP IIA2	12926
Fall 2025	PHAR 6203 - Pathophysiology & Immunology	16563	Syllabus
Spring 2025	ESE 6396 - Doctoral Research	20268
Spring 2025	ESE 6396 - Doctoral Research	23518
Spring 2025	PHAR 6477 - ISBP IIIB2	24241	Syllabus
Spring 2025	PHAR 6301 - Principles of Drug Action. IB	24784	Syllabus
Fall 2024	ESE 6396 - Doctoral Research	10075
Fall 2024	ESE 6396 - Doctoral Research	10076
Fall 2024	PHAR 6471 - ISBP IIA2	13255
Fall 2024	PHAR 6203 - Pathophysiology & Immunology	18043	Syllabus
Spring 2024	ESE 6396 - Doctoral Research	20310
Spring 2024	PHAR 6477 - ISBP IIIB2	24908	Syllabus
Spring 2024	PHAR 6301 - Principles of Drug Action. IB	25625
Fall 2023	ESE 6396 - Doctoral Research	10143
Fall 2023	PHAR 6471 - ISBP IIA2	13830
Fall 2023	PHAR 6203 - Pathophysiology & Immunology	15423	Syllabus
Spring 2023	PHAR 6477 - ISBP IIIB2	25784	Syllabus
Spring 2023	PHAR 6301 - Principles of Drug Action. IB	27035	Syllabus
Fall 2022	PHAR 6471 - ISBP IIA2	17427
Fall 2022	PHAR 6203 - Pathophysiology & Immunology	20136	Syllabus
Summer 2022	PHAR 6201 - Immunology & Immunizations	35079	Syllabus
Spring 2022	PHAR 6477 - ISBP IIIB2	28601	Syllabus
Fall 2021	PHAR 6471 - ISBP IIA2	18152
Fall 2021	PHAR 6401 - Principles of Drug Action	18148
Summer 2021	PHAR 6211 - Research Techniques	36309
Spring 2021	PHAR 6477 - ISBP IIIB2	27799
Fall 2020	PHAR 6401 - Principles of Drug Action	17635

Course Evaluations

Term	Course	Section	Evaluation
Spring 2026	PHAR 6477 - ISBP IIIB2	23778	Evaluation
Fall 2025	PHAR 6471 - ISBP IIA2	12926	Evaluation
Fall 2025	PHAR 6203 - Pathophysiology & Immunology	16563	Evaluation
Spring 2025	PHAR 6477 - ISBP IIIB2	24241	Evaluation
Spring 2025	PHAR 6301 - Principles of Drug Action. IB	24784	Evaluation
Fall 2024	PHAR 6471 - ISBP IIA2	13255	Evaluation
Fall 2024	PHAR 6203 - Pathophysiology & Immunology	18043	Evaluation
Spring 2024	PHAR 6477 - ISBP IIIB2	24908	Evaluation
Spring 2024	PHAR 6301 - Principles of Drug Action. IB	25625	Evaluation
Fall 2023	PHAR 6471 - ISBP IIA2	13830	Evaluation
Fall 2023	PHAR 6203 - Pathophysiology & Immunology	15423	Evaluation
Spring 2023	PHAR 6477 - ISBP IIIB2	25784	Evaluation
Spring 2023	PHAR 6301 - Principles of Drug Action. IB	27035	Evaluation
Fall 2022	PHAR 6471 - ISBP IIA2	17427	Evaluation
Fall 2022	PHAR 6203 - Pathophysiology & Immunology	20136	Evaluation
Spring 2022	PHAR 6477 - ISBP IIIB2	28601	Evaluation
Fall 2021	PHAR 6471 - ISBP IIA2	18152	Evaluation
Spring 2021	PHAR 6477 - ISBP IIIB2	27799	Evaluation

Bio

Awards and Honors

The 2025 High Impact and Innovative Teaching Award, The University of Texas at El Paso - The University of Texas at El Paso (11/05/2025)
The School of Pharmacy P3 Teacher of the Year - The University of Texas at El Paso (05/01/2025)
The R&I Rising Researcher Award – UTEP Health (Health Sciences, Nursing, & Pharmacy) & Social Sciences, The University of Texas at El Paso - The University of Texas at El Paso (03/01/2025)
UTEP On-Campus Student Internship Awards (2024-2025) - The University of Texas at El Paso (08/06/2024)
P3 Teacher of the Year, The School of Pharmacy at the University of Texas at El Paso, - The School of Pharmacy at the University of Texas at El Paso (07/01/2023)
The American Association of Colleges of Pharmacy (AACP) Teacher of the Year - The American Association of Colleges of Pharmacy (07/01/2023)
The Lizanell and Colbert Coldwell Foundation Research Grant - The Lizanell and Colbert Coldwell Foundation (05/01/2023)
NATIONAL EYE INSTITUTE (FED) SURE R16 Grant - NIH - NATIONAL EYE INSTITUTE (09/01/2022)
UTEP On-Campus Student Internship Awards (2022 -2023) - The University of Texas at El Paso (08/01/2022)
DOD Idea Award in Cancer Research (US Army Medical Research & Material CMD) - DOD (US Army Medical Research & Material CMD) (12/01/2020)
Top 35 Abstracts, 5th Annual IMMUNO-ONCOLOGY Young Investigators’ Forum - IMMUNO-ONCOLOGY Young Investigators’ Forum (01/01/2019-12/31/2019)
AACR‐Millennium Scholar-in-Training Award - American Association for Cancer Research (01/01/2013-12/31/2013)
Trainee Excellence Award - The University of Texas MD Anderson Cancer Center (01/01/2012-12/31/2012)
AACR-OSI Pharmaceutical Scholar-in-Training Award - American Association for Cancer Research (01/01/2007-12/31/2007)

Clinical Research, The Society of Clinical Research Associates (SOCRA) (2017)
Postdoctoral Fellow, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (2014)
Ph D in Pharmaceutical Science, University of Arizona (2008)
MS in Pharmacognosy & Microbial-Biochemical Medicine, Peking Union Medical College (2002)
B.Pharm. in Microbial-Biochemical Medicine (Micropharmaceutics), Shenyang Pharmaceutical Univer (1997)

Publications

Advances in Immunotherapy for Metastatic Uveal Melanoma: Current Progress and Future Direction Journal of Clinical Medicine (2025), Yong Qin.
Development of a Human Colorectal Carcinoma Cell-Based Platform for Studying Inducible Nitric Oxide Synthase Expression and Nitric Oxide Signaling Dynamics Frontiers in Molecular Biosciences (2025), Yong Qin.
S-nitrosylation of p53 under nitrosative stress in melanoma cells International Journal of Molecular Sciences (2025), Mariana Grigoruta, Yong Qin.
Targeting IRS-1/2 in uveal melanoma inhibits in vitro cell growth, survival and migration, and in vivo tumor growth Cancers (Basel) 14(24) (2022), Chandrani Chattopadhyay, Rajat Bhattacharya, Jason Roszik, Fatima Khan, Gabrielle A. Wells, Hugo Villanueva, Yong Qin, Rishav Bhattacharya, Sapna Patel, Elizabeth . Grimm.
Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. European Journal of Medicinal Chemistry 230 (2022), Huiqiang Wei , Wenfeng Gou, Jun Gao, Hongxin Ning, Yang Song, Deguan Li, Yong Qin, Wenbin Hou, Yiliang Li.

Presentations

Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2025), Volume Juarez, Chihuahua , Yong Qin.
Adenosine-driven immune profile in breast cancer (2025), Volume Chicago, Yong Qin.
Immune profiling of CRC identifies a potential signature associated with immunosuppression (2025), Volume Chicago, Yong Qin.
Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2025), Volume Istanbul, Turkey, Yong Qin.
Molecular and Immune Profiling of Hispanic Gastrointestinal Cancer Disparities (2024), Volume Bethesda, MD, USA, Yong Qin.

U54 Project 1: Targeting the immunosuppressive adenosine pathway to release blockade of T-cell γc cytokine signaling networks and enhance antitumor immunity in hepatocellular carcinoma (04/01/2025 - 03/30/2030) NIH
SOCS1 AS A CRUCIAL REGULATOR FOR RESISTANT UVEAL MELANOMA RESPONSE TO IMMUNOTHERAPY (09/01/2022 - 08/31/2026) NIH - NATIONAL EYE INSTITUTE (FED)
ON-CAMPUS INTERNSHIP PROGRAM Award (08/06/2024 - 08/05/2025) The University of Texas at El Paso
Eno1, a key modulator and drug target for the tumor microenvironment of cervical cancer (03/01/2024 - 02/28/2025) Lizanell and colbert coldwell foundation
Novel PHD2/HDACs hybrid inhibitors as therapeutics for advanced cervical cancer (05/01/2023 - 01/31/2024) The Lizanell and Colbert Coldwell Foundation
Development of novel therapeutics to overcome abemaciclib resistance in various cancers (01/16/2023 - 08/31/2023) The University Research Institute (URI) Award, University of Texas at El Paso, The
Molecular and immune profiling of Hispanic gastrointestinal cancer disparities (03/01/2022 - 02/28/2023) Border Biomedical Research Center (BBRC) Pilot Projects (NIH), the University of Texas at El Paso

Current/Future Courses

Term

Fall 2026

Course

ESE 6399 - Dissertation

Section

15120

Syllabus

Term

Fall 2026

Course

ESE 6296 - Doctoral Research

Section

18434

Syllabus

Term

Fall 2026

Course

ESE 6396 - Doctoral Research

Section

10067

Syllabus

Term

Fall 2026

Course

ESE 6396 - Doctoral Research

Section

10068

Syllabus

Term

Fall 2026

Course

ESE 6396 - Doctoral Research

Section

12281

Syllabus

Term

Fall 2026

Course

PHAR 6471 - ISBP IIA2

Section

12662

Syllabus

Term

Fall 2026

Course

PHAR 6203 - Pathophysiology & Immunology

Section

15437

Syllabus

Past Courses

Select Term:

Term

Spring 2026

Course

ESE 6398 - Dissertation

Section

21438

Syllabus

Term

Spring 2026

Course

ESE 6396 - Doctoral Research

Section

20235

Syllabus

Term

Spring 2026

Course

ESE 6396 - Doctoral Research

Section

23192

Syllabus

Term

Spring 2026

Course

PHAR 6477 - ISBP IIIB2

Section

23778

Syllabus

Term

Fall 2025

Course

ESE 6396 - Doctoral Research

Section

10072

Syllabus

Term

Fall 2025

Course

ESE 6396 - Doctoral Research

Section

10073

Syllabus

Term

Fall 2025

Course

PHAR 6471 - ISBP IIA2

Section

12926

Syllabus

Term

Fall 2025

Course

PHAR 6203 - Pathophysiology & Immunology

Section

16563

Syllabus

Term

Spring 2025

Course

ESE 6396 - Doctoral Research

Section

20268

Syllabus

Term

Spring 2025

Course

ESE 6396 - Doctoral Research

Section

23518

Syllabus

Term

Spring 2025

Course

PHAR 6477 - ISBP IIIB2

Section

24241

Syllabus

Term

Spring 2025

Course

PHAR 6301 - Principles of Drug Action. IB

Section

24784

Syllabus

Term

Fall 2024

Course

ESE 6396 - Doctoral Research

Section

10075

Syllabus

Term

Fall 2024

Course

ESE 6396 - Doctoral Research

Section

10076

Syllabus

Term

Fall 2024

Course

PHAR 6471 - ISBP IIA2

Section

13255

Syllabus

Term

Fall 2024

Course

PHAR 6203 - Pathophysiology & Immunology

Section

18043

Syllabus

Term

Spring 2024

Course

ESE 6396 - Doctoral Research

Section

20310

Syllabus

Term

Spring 2024

Course

PHAR 6477 - ISBP IIIB2

Section

24908

Syllabus

Term

Spring 2024

Course

PHAR 6301 - Principles of Drug Action. IB

Section

25625

Syllabus

Term

Fall 2023

Course

ESE 6396 - Doctoral Research

Section

10143

Syllabus

Term

Fall 2023

Course

PHAR 6471 - ISBP IIA2

Section

13830

Syllabus

Term

Fall 2023

Course

PHAR 6203 - Pathophysiology & Immunology

Section

15423

Syllabus

Term

Spring 2023

Course

PHAR 6477 - ISBP IIIB2

Section

25784

Syllabus

Term

Spring 2023

Course

PHAR 6301 - Principles of Drug Action. IB

Section

27035

Syllabus

Term

Fall 2022

Course

PHAR 6471 - ISBP IIA2

Section

17427

Syllabus

Term

Fall 2022

Course

PHAR 6203 - Pathophysiology & Immunology

Section

20136

Syllabus

Term

Summer 2022

Course

PHAR 6201 - Immunology & Immunizations

Section

35079

Syllabus

Term

Spring 2022

Course

PHAR 6477 - ISBP IIIB2

Section

28601

Syllabus

Term

Fall 2021

Course

PHAR 6471 - ISBP IIA2

Section

18152

Syllabus

Term

Fall 2021

Course

PHAR 6401 - Principles of Drug Action

Section

18148

Syllabus

Term

Summer 2021

Course

PHAR 6211 - Research Techniques

Section

36309

Syllabus

Term

Spring 2021

Course

PHAR 6477 - ISBP IIIB2

Section

27799

Syllabus

Term

Fall 2020

Course

PHAR 6401 - Principles of Drug Action

Section

17635

Syllabus

Term

Spring 2026

Course

PHAR 6477 - ISBP IIIB2

Section

23778

Evaluation

Term

Fall 2025

Course

PHAR 6471 - ISBP IIA2

Section

12926

Evaluation

Term

Fall 2025

Course

PHAR 6203 - Pathophysiology & Immunology

Section

16563

Evaluation

Term

Spring 2025

Course

PHAR 6477 - ISBP IIIB2

Section

24241

Evaluation

Term

Spring 2025

Course

PHAR 6301 - Principles of Drug Action. IB

Section

24784

Evaluation

Term

Fall 2024

Course

PHAR 6471 - ISBP IIA2

Section

13255

Evaluation

Term

Fall 2024

Course

PHAR 6203 - Pathophysiology & Immunology

Section

18043

Evaluation

Term

Spring 2024

Course

PHAR 6477 - ISBP IIIB2

Section

24908

Evaluation

Term

Spring 2024

Course

PHAR 6301 - Principles of Drug Action. IB

Section

25625

Evaluation

Term

Fall 2023

Course

PHAR 6471 - ISBP IIA2

Section

13830

Evaluation

Term

Fall 2023

Course

PHAR 6203 - Pathophysiology & Immunology

Section

15423

Evaluation

Term

Spring 2023

Course

PHAR 6477 - ISBP IIIB2

Section

25784

Evaluation

Term

Spring 2023

Course

PHAR 6301 - Principles of Drug Action. IB

Section

27035

Evaluation

Term

Fall 2022

Course

PHAR 6471 - ISBP IIA2

Section

17427

Evaluation

Term

Fall 2022

Course

PHAR 6203 - Pathophysiology & Immunology

Section

20136

Evaluation

Term

Spring 2022

Course

PHAR 6477 - ISBP IIIB2

Section

28601

Evaluation

Term

Fall 2021

Course

PHAR 6471 - ISBP IIA2

Section

18152

Evaluation

Term

Spring 2021

Course

PHAR 6477 - ISBP IIIB2

Section

27799

Evaluation

Yong Qin

Bio

Education

Scholarly and Creative Activity

Grants

Courses

Course Evaluations